New hope for tough leukemia: experimental drug combo enters human testing
NCT ID NCT04501120
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called lisaftoclax, alone or combined with other medicines, in people with acute myeloid leukemia that has come back or not responded to treatment. The main goals are to check safety and find the best dose. About 682 adults will take part across multiple groups.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Lisaftoclax (APG-2575), homoharringtonine, azacitidine, olverembatinib
- What this could lead to
- If it works, this could point toward a new treatment option for people with hard-to-treat acute myeloid leukemia.
- What could go wrong
- This is an early-phase trial (Phase 1b/2) focused on safety and dosing, so it is too soon to know if the drug combination will be effective. Side effects are possible, and the results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chongqing University Cancer Hospital
NOT_YET_RECRUITINGChongqing, Chongqing Municipality, China
Contact
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
-
Henan Tumor Hospital
RECRUITINGZhengzhou, Henan, China
Contact
-
Peking University People's Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact
-
Shanghai The Sixth People' s Hospital
NOT_YET_RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guandong, China
Contact
-
The First affiliated hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact
-
Union Hospital medical college Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430022, China
Contact
-
West China Hospital of Sichuan University
RECRUITINGChengdu, Sichuan, 610044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xiangya Hospital Central South University
RECRUITINGChangsha, Hunan, China
Contact
Contact
-
Zhongnan Hospital of Hunan university
RECRUITINGWuhan, Hubei, 430071, China
Contact
Contact
-
the First Affiliated Hospital, College of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310003, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
- Can a new pill take on Hard-to-Treat leukemia?
- Targeted drug aims to stop blood cancer return after transplant
- Epigenetic drugs aim to stop cancer return after transplant in kids
- Immune-Boosting drug aims to outsmart Hard-to-Treat blood cancers
- Three-Drug cocktail aims to tame transplant complications in blood cancer patients